PTC Therapeutics, Inc. beat EPS estimates 31% of the time across 16 reported quarters (5 beats, 11 misses), averaging -16.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $0.92 | not reported | not reported | Q2 FY26 call |
| Q1 FY26 | not reported | $-0.03 | not reported | not reported | |
| Q3 FY25 | not reported | $0.20 | not reported | not reported | |
| Q2 FY25 | $-1.07 | $-0.83 | +22.4% | Beat | |
| Q1 FY25 | not reported | $10.04 | not reported | not reported | |
| Q4 FY24 | not reported | $-0.24 | not reported | not reported | |
| Q3 FY24 | $-1.54 | $-1.39 | +9.7% | Beat | |
| Q2 FY24 | not reported | $-1.16 | not reported | not reported | |
| Q1 FY24 | $-1.21 | $-1.20 | +0.8% | Beat | |
| Q4 FY23 | not reported | $-0.24 | not reported | not reported | |
| Q3 FY23 | $-0.85 | $-1.76 | -107.1% | Miss | |
| Q2 FY23 | $-1.58 | $-2.66 | -68.3% | Miss |
Back to PTCT overview · PTCT holders · PTCT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.